VISX Receives FDA Panel Approval for Treatment of Hyperopic Astigmatism.Business Editors & Health/Medical Writers SANTA CLARA, Calif.--(BW HealthWire)--May 12, 2000 VISX, Inc. (Nasdaq:VISX) announced today that the U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) Ophthalmic Devices Advisory Panel has unanimously recommended approval with conditions for the VISX STAR(TM) Excimer Laser A gas laser in which a very short electrical pulse excites a mixture containing a halogen such as fluorine and a rare gas such as argon or krypton. It produces a brief, intense pulse of ultraviolet light. Systems for the treatment of hyperopic astigmatism hyperopic astigmatism n. Astigmatism in which one meridian is hyperopic while the one at a right angle to it is without refractive error. . VISX is the worldwide leader in the development of refractive refractive capacity to refract light. refractive error a difference between the focal length of the cornea and lens, and the length of the eye, resulting in myopia or hyperopia. laser technology. VISX systems are commercially available in the United States and markets worldwide. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion